Adjemian, J., Baggs, J., Cox, E., Danner, R. L., Dekker, J., Farley, J., . . . Kadri, S. S. (2025). Adjunctive linezolid versus clindamycin for toxin inhibition in β-lactam-treated patients with invasive group A streptococcal infections in 195 US hospitals from 2016 to 2021: A retrospective cohort study with target trial emulation. The Lancet Infectious Diseases, 25(3), 265-275. https://doi.org/10.1016/S1473-3099(24)00507-3

Adjemian, Jennifer, et al. "Adjunctive Linezolid Versus Clindamycin for Toxin Inhibition in β-lactam-treated Patients with Invasive Group A Streptococcal Infections in 195 US Hospitals from 2016 to 2021: A Retrospective Cohort Study with Target Trial Emulation." The Lancet Infectious Diseases 25, no. 3 (2025): 265-275. https://doi.org/10.1016/S1473-3099(24)00507-3.

Adjemian, Jennifer, et al. "Adjunctive Linezolid Versus Clindamycin for Toxin Inhibition in β-lactam-treated Patients with Invasive Group A Streptococcal Infections in 195 US Hospitals from 2016 to 2021: A Retrospective Cohort Study with Target Trial Emulation." The Lancet Infectious Diseases, vol. 25, no. 3, 2025, pp. 265-275, https://doi.org/10.1016/S1473-3099(24)00507-3.